A multi-center open-label parallel group randomized controlled trial to compareiGlarLixi versus premixed insulin in patients with type 2 diabetes who have failedto achieve glycemic control with basal insulin and oral antidiabetic agents

drug protocol number
LPS15017
drug sponsor
Sanofi
drug study
Insulin glargine/Lixisenatide
drug trial site
King Fahad Medical City (Riyadh)
drug status
Ongoing
drug phase